E7130
E7130 is a microtubule inhibitor, which ameliorates the tumor microenvironment through suppression of cancer-associated fibroblasts (CAF) and promotion of tumor vasculature remodeling.
For research use only. We do not sell to patients.
- Formula: C58H83NO17
- Molecular Weight:1066.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
E7130 inhibits microtubule dynamics and exhibits anti-proliferative efficacy in cancer cells KPL-4, OSC-19, FaDu and HSC-2, with IC50s of 0.01-0.1 nM[1].
E7130 (0.15 nM) inihibits TGF-β-induced myofibroblast transdifferentiation through disruption of microtubule network formation, and thereby deactivates the PI3K/AKT/mTOR pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BJ cells
-
Concentration:0.15 nM
-
Incubation Time:48 h
-
Result:Inhibited TGF-β-induced α-SMA expression in BJ cells without growth inhibitory activity.
-
Cell Line:BJ cells
-
Concentration:0.15 nM
-
Incubation Time:48 h
-
Result:Decreased levels of pAKT and pS6.
In Vivo
E7130 (45-180 μg/kg, i.v.) reduces the α-SMA-positive CAFs, the E7130-CTX combination modulates the phenotypes of the fibroblasts in FaDu SCCHN xenograft BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FaDu SCCHN xenograft BALB/c mice[1]
-
Dosage:45-180 μg/kg
-
Administration:i.v.
-
Result:Reduced the α-SMA-positive CAFs, modulated the phenotypes of the fibroblasts with combination of CTX.
-
Animal Model:HSC-2 SCCHN xenograft BALB/c mice[1]
-
Dosage:90 μg/kg
-
Administration:i.v.
-
Result:Increased MVD, inhibited tumor growth.
Increased survival rate with combination of CTX.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Molecular Weight 1066.28
-
Formula C58H83NO17
-
SMILES
O=C(C[C@@H]1O[C@@]([C@H](O[C@]2(CC3)O[C@H]4[C@H]5C2)[C@H](O5)[C@@]4([H])O6)([H])[C@]6([H])CC1)O[C@H]([C@H]7C)[C@H](C[C@H]8O[C@@H](CC[C@H]9C(C[C@@H]3O9)=C)C[C@@H](C)C8=C)O[C@@]([C@@]7([H])O%10)([H])C[C@@]([C@@]%10([H])C%11)([H])O[C@@]%11(O%12)C[C@]([C@]%12([H])[C@@H](C)C%13)([H])O[C@@]%14%13C[C@H](C)[C@]%15([H])O[C@H](CN)[C@H](O)C[C@]%15([H])O%14
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Multiplex immunofluorescence IHC
Multiplex immunofluorescence IHC detects multiple protein biomarkers in one tissue section by sequential antibody staining, HRP-mediated tyramide fluorophore deposition, heat-mediated antibody stripping, nuclear counterstaining, multispectral imaging, spectral unmixing, and digital cell phenotyping; TSA deposits fluorophore near the antigen so the fluorescence signal remains after primary and secondary antibodies are removed, enabling repeated staining cycles, including with antibodies from the same host species. Classic FFPE tumor immune-profiling applications use panels such as CD3, CD8, CD68/CD163, FOXP3, PD-1, PD-L1, pancytokeratin, Ki67, and DAPI to identify tumor cells, immune-cell subsets, checkpoint-marker expression, co-expression phenotypes, cell density, and spatial relationships in the tumor microenvironment.
-
Multiplex immunohistochemistry
Multiplex immunohistochemistry (mIHC), also known as tyramide dignal amplification (TSA), is an enzymatic detection method that uses horseradish peroxidase (HRP) to perform high-density in-situ labeling of target proteins or nucleic acids.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)